Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ABBVIE, LDA

NIF 510229050
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €7,125,089 65 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €7,125,089 65 contracts
A2 · Late Publication €14,991,522,363 3,288 contracts
Contract published to BASE more than 10 days after the signing date
LOW €14,991,522,363 3,288 contracts
A5 · Threshold Splitting €20,890,047 205 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €20,890,047 205 contracts
A6 · Low Competition €6,149,428 55 contracts
Only one bidder participated in a competitive procedure
MEDIUM €6,149,428 55 contracts
A9 · Price Overrun €27,187 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €27,187 1 contracts
A9 · Abnormal Price Reduction €18,573,654,243 1,503 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €18,573,654,243 1,503 contracts
C3 · Missing Mandatory Fields €10,925,430 99 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €10,925,430 99 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

333
€720,560,755
160
€715,003,390
76
€699,740,983
58
€672,102,082
77
€653,503,769
190
€641,393,802
66
€637,691,765
43
€633,136,345
33
€613,211,255
480
€610,200,235
168
€605,092,562
82
€602,138,110
42
€584,982,415
212
€580,824,017
37
€575,524,525
150
€567,225,194
252
€556,074,813
121
€543,555,653
32
€526,670,650
122
€512,750,093
Page 1 of 3 · 59 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 5 · 205 contracts

Medicamentos usados em afeções oculares e otorrinolaringológicas
PT · 13151770 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€19,203 2026-01-21
IMUNOMODULADORES - ADALIMUMAB
PT · 12030369 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,000 2025-12-09
1748225 Mirvetuximab soravtansina 5 mg/ml Sol inj Fr 20 ml IV Fim PAP custo Zero – Ano 2025 – Ano 2025
PT · 11979958 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€73,626 2025-11-26
251Y000335 - AQUISIÇÃO DE UPADACITINIB 45 MG COMP LP
PT · 11928504 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,771 2025-11-12
251Y000329/28341-Medicamentos ao abrigo A.Q. 2023/0671
PT · 11945753 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€144,330 2025-11-10
Q1/2318/2025 - AGREGAÇÃO URGENTE - MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 11977059 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,294,078 2025-10-22
ADCM 3967/25 - MEDICAMENTOS DIVERSOS
PT · 11759979 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€71,919 2025-09-12
Medicamentos
PT · e11e2df13a7eb8fa01de · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€4,800 2025-09-09
Medicamentos
PT · ad51dd44a2860bffe3c6 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,800 2025-08-19
MEDICAMENTOS EXCLUSIVOS ABBVIE, LDA
PT · 11667337 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€74,881 2025-07-11
ADCM3064/25 - MEDICAMENTOS DIVERSOS
PT · 11616075 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€149,723 2025-07-11
Medicamentos
PT · 11532516 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,310 2025-06-12
UPADACITINIB 30MG COMP LP (PC.02341.2025)
PT · 11638953 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,633 2025-05-30
Medicamentos
PT · 11371173 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€72,968 2025-04-17
PQ/1221/2025 - UPADACITINIB _ CPA 55_2022
PT · 11450032 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€148,487 2025-04-10
050101032025-EPCORITAMAB SOL INJ FR SC
PT · 11334668 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€147,500 2025-02-26
050100302025 C/ BASE NO CPA 2024_961
PT · 11758244 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€72,989 2025-02-06
VÁRIOS MEDICAMENTOS
PT · 11191927 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,862 2025-01-20
Medicamentos
PT · 11324899 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,849 2025-01-08
Fornecimento de substância ativa: Adalimumab 80mg
PT · 11175219 · Ajuste Direto Regime G...
A5 · Threshold Splitting C3 · Missing Mandatory Fields +1
€4,800 2024-12-20
MEDICAMENTOS
PT · 11130032 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,145 2024-12-18
Aquisição de ADALImumab 40 mg/0.4 ml Sol inj Caneta 0.4 ml SC - Abbvie
PT · 11067757 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€19,200 2024-12-05
VÁRIOS MEDICAMENTOS
PT · 11075256 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,493 2024-11-28
VÁRIOS MEDICAMENTOS
PT · ec6c64fea0b469c7bfa7 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€19,493 2024-11-28
050100232025 - Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 494/2023 Medicamentos para a Hepatite C Crónica para aquisição de Medicamentos para a Hepatite C Crónica
PT · 11209935 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€71,500 2024-11-27
MEDICAMENTOS
PT · 10979933 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€71,694 2024-10-09
VÁRIOS MEDICAMENTOS
PT · 10962746 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,243 2024-10-08
VÁRIOS MEDICAMENTOS
PT · 10965395 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,840 2024-10-02
VÁRIOS MEDICAMENTOS
PT · 10939039 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,555 2024-09-24
Upadacitinib
PT · 11263276 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€72,530 2024-09-23
2024006890 - ARM60-IMPLANTE XEN 45
PT · 10926826 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,950 2024-09-03
MEDICAMENTOS
PT · 10897755 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€74,294 2024-08-28
Aquisição de UPADACITINIB [30 MG; COMP LP] ao abrigo do acordo quadro 2022/55
PT · 10989941 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€73,650 2024-08-22
J1/2148/2024 Agreg. Urg. ADALIMUMAB – ABBVIE - DOENTES EM TRATAMENTO
PT · 10819782 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,800 2024-07-12
Aquisição de Foslevodopa 240 mg/ml + Foscarbidopa 12 mg/ml Sol inj Fr 10 ml SC e Cabozantinib 60mg ao abrigo do Acordo Quadro 2023/671
PT · 10933167 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€144,991 2024-06-20
MEDICAMENTOS DIVERSOS
PT · 10769925 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€149,980 2024-05-31
ADALIMUMAB 40MG CANETA 0.4 ML (PC.00749.2024)
PT · 10653849 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€144,000 2024-03-08
VÁRIOS MEDICAMENTOS
PT · 10601496 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,617 2024-03-05
Aquisição de ADALIMUMAB SC 40 MG0,4 ML SOL INJ CAN ao Lab. Abbvie para a ULSASI para o ano de 2024
PT · 10583586 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€72,000 2024-02-26
AQUISIÇÃO DE ADALIMUMAB 40 MG/0.4 ML SOL INJ CANETA 0.4 ML SC - FARMACOVIGILÂNCIA
PT · 10937514 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€144,000 2024-02-20
MEDICAMENTOS
PT · 6a20711d7b7321302bb6 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€4,800 2024-02-20
PQ/735/2024 - VENETOCLAX 10,50,100MG
PT · 10942809 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€74,128 2024-02-16
06/00052.11/2024 - Aquisição de Medicamentos usados nas Afeções Oculares e Otorrinolaringológicas ao abrigo do Acordo Quadro 2021/49
PT · 10556732 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€142,744 2024-01-11
AQUISIÇÃO DE MEDICAMENTOS DCI - COM PARECER CIENTIFICO - ANO DE 2024 - SPMS
PT · 10807809 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,314,968 2024-01-04
DEXAmetasona 700 µg Impl intravítreo Aplic Intravítreo
PT · 11700558 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,897 2023-12-14
2023010793 - ARM60-IMPLANTE XEN 45
PT · 10579328 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,950 2023-12-04
050103662023 - C/BASE NO CPA 2021_67 - Glecaprevir 100 mg + Pibrentasvir 40 mg Comp
PT · 10359601 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€72,288 2023-11-16
MEDICAMENTOS
PT · 59e39268b860fc890944 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,800 2023-11-15
ADALIMUMAB 40MG CANETA 0.4 ML (PC.01267.2023)
PT · 10402147 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€144,000 2023-11-09
MEDICAMENTOS
PT · e9a4bb05ed6f02af2777 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,800 2023-10-11
Next →
Overview
Total Value Won
€18,846,490,806
Contracts Won
4,728
Score 160085 · CRITICAL RISK
NIF
510229050
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.P. [P-93b9]
    Gerente
    since 2017-09-06
  • C.M. [P-a59e]
    Gerente
    since 2019-10-03
  • C.M. [P-a59e]
    Gerente
    since 2022-07-11
  • C.M. [P-a59e]
    Gerente
    since 2025-07-08
  • C.R. [P-5fd1]
    Gerente
    since 2020-02-19
  • F.V. [P-260a]
    Gerente
    since 2013-01-03
  • G.G. [P-b5cc]
    Gerente
    since 2023-03-31
  • G.G. [P-b5cc]
    Gerente
    since 2025-07-08
  • L.C. [P-dfea]
    Gerente
    since 2023-09-27
  • M.I. [P-bb79]
    Gerente
    since 2015-06-11
  • N.G. [P-e1e3]
    Gerente
    since 2026-04-08
  • O.M. [P-8e9a]
    Gerente
    since 2022-07-11
  • R.A. [P-6f67]
    Gerente
    since 2019-04-30
  • W.J. [P-08cb]
    Gerente
    since 2013-01-03
  • A.A. [P-0394]
    Sócio
    since 2012-04-05
  • A.A. [P-0394]
    Sócio
    since 2012-08-01
  • A.S. [P-ec2b]
    Sócio
    since 2012-04-05
  • A.S. [P-ec2b]
    Sócio
    since 2012-08-01
  • A.C. [P-59a3]
    Sócio
    since 2021-07-05
  • A.S. [P-f521]
    Sócio
    since 2021-07-05
  • A.D. [P-368d]
    Gerente
    2022-07-11 → 2023-09-27
  • C.P. [P-93b9]
    Gerente
    2019-04-30 → 2020-02-19
  • C.R. [P-5fd1]
    Gerente
    2022-07-11 → 2023-03-31
  • E.L. [P-442d]
    Gerente
    2012-04-05 → 2015-04-13
  • F.A. [P-b4fa]
    Gerente
    2012-04-05 → 2013-01-03
  • F.V. [P-260a]
    Gerente
    2015-04-13 → 2015-06-04
  • K.K. [P-2ee1]
    Gerente
    2022-07-11 → 2025-01-06
  • L.C. [P-dfea]
    Gerente
    2025-07-08 → 2026-04-08
  • M.I. [P-bb79]
    Gerente
    2019-04-30 → 2019-10-03
  • O.M. [P-8e9a]
    Gerente
    2025-07-08 → 2026-03-30
  • R.J. [P-33a8]
    Gerente
    2015-04-13 → 2017-07-24
  • T.C. [P-d023]
    Gerente
    2012-04-05 → 2013-01-03
  • W.J. [P-08cb]
    Gerente
    2015-04-13 → 2019-04-30
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned